about
Clinically and pharmacologically relevant interactions of antidiabetic drugsGastrointestinal bleeding during low dose acetylsalicylic acid. Is Godamed-100 TAH an alternative to conventional ASS preparations?Pharmacological MRI (phMRI) of the Human Central Nervous System.Statin treatment in hypercholesterolemic men does not attenuate angiotensin II-induced venoconstriction.Motivations for (non)participation in population-based health studies among the elderly - comparison of participants and nonparticipants of a prospective study on influenza vaccination.The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?Effects of Ginkgo biloba extract EGb 761® on cognitive control functions, mental activity of the prefrontal cortex and stress reactivity in elderly adults with subjective memory impairment - a randomized double-blind placebo-controlled trial.Assessing the eligibility of a non-invasive continuous blood pressure measurement technique for application during total intravenous anaesthesia.Olmesartan for the treatment of arterial hypertension.Establishment of a cohort for deep phenotyping of the immune response to influenza vaccination among elderly individuals recruited from the general population.Prescriptions of systemic antibiotics for children in Germany aged between 0 and 6 years.New therapeutic efforts and upcoming developments in the field of diabetes medicine and endocrinology.Editorial: Closing sale of innovative treatment options for the treatment of diabetes and metabolic disorders?Dedicated to evidence-based medicine and the evaluation of new therapeutic approaches in the field[Current status of antihypertensive drug treatment in primary care practice at launch of the new renin inhibitor aliskiren (RASANT)].Reproducibility of dorsal hand vein responses to phenylephrine and prostaglandin F2 alpha using the dorsal hand vein compliance method.Reoccurrence of levofloxacin-induced tendinitis by phenoxymethylpenicillin therapy after 6 months: a rare complication of fluoroquinolone therapy?ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.Characterization of vascular reactivity in dorsal hand veins after oral rosiglitazone treatment in healthy subjects.Usability of Functional MRI in Clinical Studies for Fast and Reliable Assessment of Renal Perfusion and Quantification of Hemodynamic Effects on the Kidney.Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.Cardiovascular risk in obese hypertensive patients taking various antihypertensive drugs.The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients.Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects[Pharmacologic interactions as the cause of a loss of effectiveness of local anesthetics]Asymptomatic statin-induced rhabdomyolysis after long-term therapy with the hydrophilic drug pravastatin[Fractures of vital teeth under chronic pain therapy with oxycodone]Smart textiles: a new drug delivery system for symptomatic treatment of a common coldCandesartan treatment for peripheral occlusive arterial disease after stent angioplasty : a randomised, placebo-controlled trialCardiovascular Parameters during Submaximal Exercise following Submucous Administration of Articaine : A Comparison with Lidocaine and Placebo in Young Healthy VolunteersFirst patient-centered drug information service in Germany--a descriptive study[Recent examples for drug (developments) in primary, secondary and tertiary prevention][Drug information for patients -- unmet needs, evaluation and influence on the compliance][Antihypertensive drug therapy--combination of AT1-receptor blocker and betablocker]Managing hypertension among nursing-home residents and community-dwelling elderly in Germany: a comparative pharmacoepidemiological study[Benefits and risks of current pharmacotherapy in the treatment of type 2 diabetes]Characterization of local vascular effects of the nitric oxide inhibitor NG-monomethyl-L-arginine on dorsal hand veins[Pharmacological concepts for the treatment of obesity - a therapeutic meander?]New players in the field of antiplatelet and anticoagulant therapy in coronary heart disease - current therapeutic issues and hot topics[Personalized medicine and type-2 diabetes: pharmakogenetic aspects of drug therapy]
P50
Q26752468-D9378447-1E43-490F-8B51-8C09AB6DD316Q28174060-0DE124D6-9EC2-40FF-B7C8-D1B5A1C58B7CQ30991037-F3BEEBDB-00D5-4963-89AD-B3AA3D4B5EF1Q35284008-C67BDAD6-2956-42DA-8837-4EAE65DA8A7CQ36266649-717E28D2-2898-4D82-8548-7A2EA9C1DDC1Q37362674-73D98F7B-715E-43BA-A08B-1E0187D31F9AQ37375548-20F12BCC-D8CB-421E-92AA-63F99883A2AFQ40011190-59D66511-E8C3-416D-8BA5-9BEFA544317CQ40076763-691A65BB-4B6C-4D6C-976B-16384C002000Q40258020-64CE6DC7-B058-4639-9CFD-334BC3A73884Q40563334-5DEEC242-EDE8-4253-BC37-8AE647D42BB0Q42416634-5CB8018A-AEF4-41E7-9089-5F072EB8B060Q42416649-6AE062B5-449C-4111-ABBE-641BBC2EF629Q42416662-E54E09FC-AF9E-4533-924C-12B13A1F905FQ43116133-950E8723-EC94-49A0-99E2-43FE483B7E42Q44362842-4400D34A-4DF0-4147-8B7A-F4F9C7FF7C0AQ44447607-739ACC43-FC7A-4E88-870A-783C35EF92F0Q45268057-EE102FB3-8C49-4C47-AF91-616DD8B97E68Q46792696-1983A3E2-D63C-49C4-AE8F-8A70DDD3E4A3Q47618322-AC87F851-E1FF-40D6-8D6C-694DD3F72A3CQ48212691-3951012C-41F9-4C6B-8E57-5D8F11ACC31DQ51906602-3CE7531D-1B38-422F-80CF-E9BFD036A5BEQ52676366-5B93F1F5-F535-4CC0-AEF4-ECBCE1145BA2Q79456162-ECDF1C3A-EB4D-4498-B133-5AC2E94955F2Q79750384-33C2B756-3FE1-4BD8-92F7-E828D175FA48Q80016109-9FAA5F40-A2AC-464C-B710-72C12D4192B0Q80131098-5BB10B01-5DAB-4754-8AAD-F5F31D71C60FQ80177917-5DC81593-13F6-494C-840D-B3151BA57D94Q80379020-D6C2361D-6B07-4AE1-9347-7C834BF408CCQ80397785-657A7557-2530-4BA3-BB75-66B0B2AEF5B4Q80952327-714A5948-9F26-47CA-92DA-737788DCAB1CQ81416915-3EF8A079-3965-4290-86CF-E97A00105B00Q81824852-D5F646FD-FC1B-4C11-A923-540689ED80B8Q82528470-FB1592DE-90CF-47B2-A348-411DC076A6B5Q83154282-76373A3E-8D6D-4A15-A9B5-CE9EE8ABFA20Q83568914-9D9C4278-AD40-43BD-B2A3-1B5B9BDE4FB6Q84087090-E6C3A6D7-D1BD-4F78-B49A-6062341158DCQ84645791-9C39FCA9-F36D-4179-9F63-7FC42FB54494Q84910616-8EC806F1-426B-412D-AF1B-986F33BD5FCBQ87184079-672EDF43-4C24-4A81-BCE9-0FCCED4AACFD
P50
description
researcher ORCID ID = 0000-0002-6779-0057
@en
wetenschapper
@nl
name
Christoph Schindler
@ast
Christoph Schindler
@en
Christoph Schindler
@es
Christoph Schindler
@nl
type
label
Christoph Schindler
@ast
Christoph Schindler
@en
Christoph Schindler
@es
Christoph Schindler
@nl
prefLabel
Christoph Schindler
@ast
Christoph Schindler
@en
Christoph Schindler
@es
Christoph Schindler
@nl
P1153
7101692457
P31
P496
0000-0002-6779-0057